Debiopharm and Ipsen announced renewal of their Decapeptyl® agreement, which extends their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl® across Europe and certain Asian and African markets.
Under the renewed agreement, both parties will co-develop novel formulations and explore additional indications for other patient populations with high unmet needs.
“Our continued partnership remains critical to ensure that patients maintain access to Decapeptyl® therapy for their various conditions. Furthermore, this renewed agreement represents an opportunity to refine and refocus our collaboration by further exploring our co-development capacity to potentially identify how Decapeptyl® can respond to more unmet patient needs,” Thierry Mauvernay, President & Delegate of the Board Group, Debiopharm said.
“We are delighted to renew and extend this partnership with Debiopharm. This collaboration has been - and continues to be - a testament to our commitment to patients and our shared passion with strategic partners,” Ivana Magovčević-Liebisch, Executive Vice-President, Chief Business Officer said.
Decapeptyl® (triptorelin pamoate) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH), currently available in three sustained-release formulations (1, 3 and 6 months). First registered in France in 1986, triptorelin is currently marketed in more than 80 countries, being the market leader in many territories worldwide. The alliance between Debiopharm and Ipsen for Decapeptyl® has successfully delivered sustained market growth with €372.6 million total sales in 2018, representing 8.1% annual growth.